Allison Betof Warner, MD, PhD, assistant professor and assistant attending at Memorial Sloan Kettering Cancer Center, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with advanced 

The findings demonstrated a confirmed complete response rate of 40%, which is a number that has not been seen in the field of melanoma before. The combination also appears durable, says Warner. Targeted therapies are known for having great responses upfront but tend not to be long lasting. The combination of immunotherapy appears to make this treatment durable, she notes.

There were also concerns about overlapping toxicities in this triplet regimen. However, there were not any huge safety signals, and most patients can tolerate the combination.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Immunotherapy in Melanoma

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Melanoma & Skin Cancer

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

SMR Congress

Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.

Dr. Warner Discusses Findings from COMBI-i Trial in Melanoma